When will sotoraxibu (AMG510) be available in China?

Sotoracib (AMG510) has not yet been officially approved for marketing in China. However, as China's medical regulatory authorities continue to approve new drugs, and given China's importance in the field of cancer treatment, it is likely that sotorasibu will be approved by China at some point in the future and become one of the treatment options for Chinese lung cancer patients.

China's drug approval process usually includes multiple stages such as clinical trial data submission, review and approval. After the application is submitted, China's National Medical Products Administration (NMPA) will conduct a strict review of sotoraxib's clinical trial data, drug quality and safety. Once sotoracib is approved, it will become one of the legal drug options for Chinese doctors to treat patients with KRAS G12C mutated non-small cell lung cancer (NSCLC).

China has one of the largest lung cancer patient groups in the world, so the Chinese market has huge potential and demand for the introduction of innovative anti-cancer drugs. As a targeted therapy drug, sotoracib has shown certain efficacy in clinical trials against the KRAS G12C mutation, so it is likely to attract the attention of Chinese doctors and patients.

However, the specific time for sotorasibu to be approved in China depends on a variety of factors, including the integrity and quality of clinical trial data, the safety and effectiveness of the drug, and the work efficiency of the approval agency. In addition, the price and availability of sotorasibu in the international market may also affect its promotion and application in the Chinese market.

In general, although sotorasibu has not yet been approved for marketing in China, as the approval process by Chinese medical regulators continues, it is likely to become a treatment option for Chinese lung cancer patients at some point in the future, bringing new hope and opportunities to this patient group.